Vaccitech Limited
Magdalen Centre
The Oxford Science Park
1 Robert Robinson Avenue
Oxford
OX4 4GA
United Kingdom
Tel: +44-01865-818808
Website: https://www.vaccitech.co.uk/
About Vaccitech Limited
Vaccitech is a spin-out company from the University of Oxford’s Jenner Institute, one of the oldest and most renowned vaccine research centres in the world.
The founders of the company are Professor Adrian Hill (Director of the Jenner Institute) and Professor Sarah Gilbert (Lead in influenza and MERS), who combine their exceptional scientific skills with regulatory and manufacturing experience. The management team has decades of experience in the development of vaccine products.
Vaccitech is engaged in Phase 2 clinical programs for universal influenza and prostate cancer, Phase 1 for MERS, and preclinical programs for 3 other therapeutic infectious diseases indications. and is actively developing an internal pipeline of therapeutic candidates.
YEAR FOUNDED:
2016
LEADERSHIP:
Founders: Professor Adrian Hill and Professor Sarah Gilbert
TECHNOLOGY
Please click here for Vaccitech's technology
54 articles with Vaccitech Limited
-
Vaccitech Promotes Gemma Brown as Chief Financial Officer
9/20/2022
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer (CFO).
-
Vaccitech to Present at Upcoming September 2022 Investors Conferences
9/7/2022
Vaccitech plc announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.
-
Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
8/9/2022
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter ended June 30, 2022 and provided an overview of the Company’s recent corporate developments.
-
Vaccitech to Present at the William Blair Biotech Focus Conference 2022
7/7/2022
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 in New York, July 11 to 12.
-
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.
-
Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1
6/22/2022
Vaccitech plc announced an update to the interim analysis of safety and efficacy data from the HBV002 study, which is being presented as a poster at the 2022 EASL International Liver CongressTM by Professor Ellie Barnes, Professor of Hepatology and Experimental Medicine at the University of Oxford.
-
Vaccitech to Present at the Jefferies Healthcare Conference - June 06, 2022
6/6/2022
Vaccitech plc announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.
-
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
5/20/2022
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022.
-
Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments
5/11/2022
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the first quarter ended March 31, 2022, and provided an overview of the Company’s recent corporate developments.
-
Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®
4/6/2022
Vaccitech plc, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, announced that it has been notified of the commencement of royalty payments relating to commercial sales of Vaxzevria®.
-
Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments
3/25/2022
Vaccitech plc (NASDAQ: VACC) today announced its financial results for the full year ended December 31, 2021 and provided an overview of the Company’s recent corporate developments.
-
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
3/7/2022
Vaccitech plc today announced that the Company’s Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics LandscapeLive webcast will be at 8:30 a.m. EST on January 25
1/13/2022
Vaccitech plc (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader (“KOL”) event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape.
-
Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines
12/14/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines, today announced that it has acquired US-based Avidea Technologies, Inc. (“Avidea”).
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
12/7/2021
Vaccitech plc today announced a promising interim analysis of safety and efficacy data from the HBV002 study, including a review of surface antigen (HBsAg) levels in CHB patients.
-
Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference
11/24/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, and Georgy Egorov, Chief Financial Officer, are participating at the 33rd Annual Virtual Piper Sandler Healthcare Conference November 30th to December 2nd, 2021.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
11/12/2021
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced results from ongoing Phase 1 and Phase 1b/2a clinical trials of VTP-300, an immunotherapy candidate in development for the treatment of CHB infection.